ទំព័រដើម › Non-Small Cell Lung Cancer › កាលីហ្វ័រញ៉ា › Sacramento
ការសាកល្បងគ្លីនិកសម្រាប់ Non-Small Cell Lung Cancer នៅក្នុង Sacramento, CA
ការសិក្សាចំនួន 29 សម្រាប់ Non-Small Cell Lung Cancer កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Sacramento (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
កំពុងជ្រើសរើសដំណាក់កាល 3
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- និង 1 ទៀត
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
កំពុងជ្រើសរើសដំណាក់កាល 3
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Buhler Specialty Pavilion, Sacramento
- Sutter Medical Center, Sacramento Infusion Center, Sacramento
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- UC Davis Comprehensive Cancer Center, Sacramento
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- UC Davis Comprehensive Cancer Center, Sacramento
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
កំពុងជ្រើសរើសដំណាក់កាល 2
- UC Davis Cancer Center (Data Collection Only), Sacramento
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- UC Davis Comprehensive Cancer Center, Sacramento
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of California Davis Comprehensive Cancer Center, Sacramento
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of California Davis Comprehensive Cancer Center, Sacramento
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of California Davis Comprehensive Cancer Center, Sacramento
- University of California, Davis Medical Center, Sacramento
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
កំពុងជ្រើសរើស
- University of California, Davis, Sacramento
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- UC Davis, Davis Comprehensive Cancer Center, Sacramento
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 3
- Sutter Institute for Medical Research, Sacramento
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of California Davis, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Kaiser Permanente Downtown Commons, Sacramento
- Mercy Cancer Center - Sacramento, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
- និង 1 ទៀត
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
កំពុងជ្រើសរើសដំណាក់កាល 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- VA Northern California Health Care System, Mather, CA, Sacramento
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of California-Davis, Sacramento
ការសាកល្បងសម្រាប់ Non-Small Cell Lung Cancer នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 145
- New York City, NYការសិក្សា 121
- Arlington, VAការសិក្សា 104
- Nashville, TNការសិក្សា 97
- Boston, MAការសិក្សា 90
- Los Angeles, CAការសិក្សា 87
- St. Louis, MOការសិក្សា 73
- Chicago, ILការសិក្សា 61
- Baltimore, MDការសិក្សា 60
- San Antonio, TXការសិក្សា 59
- Columbus, OHការសិក្សា 57
- Washington, DCការសិក្សា 55
ការសិក្សាផ្សេងទៀតនៅក្នុង Sacramento
- មហារីកសួតការសិក្សា 22
- មហារីកទ្រូងការសិក្សា 20
- មហារីកតូចការសិក្សា 19
- មហារីកដែលរីករាលដាលការសិក្សា 16
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 12
- បេះដូងខ្សោយការសិក្សា 12
- មហារីកតំបក់ការសិក្សា 12
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 11
- មហារីកពោះវៀនធំការសិក្សា 11
- មហារីកប្លោកទឹកនោមការសិក្សា 10
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 10
- ជំងឺទឹកនោមផ្អែមប្រភេទ ២ការសិក្សា 9
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។